Related Experiment Video
Updated: Apr 11, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
TGF-β signaling and its targeting for glioma treatment
Jianfeng Han1, Christopher A Alvarez-Breckenridge2, Qi-En Wang3
1Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University Columbus, Ohio 43210, USA ; The Ohio State University Comprehensive Cancer Center Columbus, Ohio 43210, USA.
Abstract:
Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine, secreted by a variety of cells including immune cells, tumor cells, and stromal cells. TGF-β signaling is dysregulated in cancer patients, and this aberrant signaling at least in part contributes to initiation and progression of many cancers including glioma. The dysregulated signaling components provide molecular targets for the treatment of glioma. In this article, we review TGF-β signaling and its targeting in glioma.
Insights
Transforming growth factor-beta (TGF-β) signaling is altered in cancer, promoting glioma development. Targeting these dysregulated TGF-β pathways offers potential therapeutic strategies for glioma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Transforming growth factor-beta (TGF-β) is a cytokine produced by various cells, including immune, tumor, and stromal cells.
- Dysregulated TGF-β signaling is implicated in the initiation and progression of numerous cancers.
- Aberrant TGF-β signaling is a key factor in glioma development and advancement.
Purpose of the Study:
- To review the role of TGF-β signaling in glioma.
- To discuss the targeting of TGF-β signaling components as a therapeutic strategy for glioma.
Main Methods:
- Literature review of studies on TGF-β signaling in cancer and glioma.
- Analysis of dysregulated TGF-β pathway components in glioma.
- Examination of potential therapeutic targets within the TGF-β pathway.
Main Results:
- TGF-β signaling plays a significant role in multiple stages of glioma.
- Specific components of the TGF-β pathway are frequently dysregulated in glioma.
- Targeting these dysregulated components shows promise for glioma treatment.
Conclusions:
- TGF-β signaling is a critical mediator in glioma pathogenesis.
- Targeting TGF-β pathways represents a viable therapeutic approach for glioma.
- Further research into TGF-β targeting strategies could lead to novel glioma treatments.
